![]() | |
Clinical data | |
---|---|
Other names | MGC; Megestrol hexanoate; Megestrol 17α-caproate; 17α-Hydroxy-6-dehydro-6-methylprogesterone 17α-caproate; 17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17α-caproate |
Drug class | Progestin; Progestogen; Progestogen ester |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C28H40O4 |
Molar mass | 440.624 g·mol−1 |
3D model ( JSmol) | |
| |
|
Megestrol caproate, abbreviated as MGC, is a progestin medication which was never marketed. [1] [2] It was developed in Russia in 2002. [1] In animals, MGC shows 10-fold higher progestogenic activity compared to progesterone when both are administered via subcutaneous injection. [1] In addition, MGC has no androgenic, anabolic, or estrogenic activity. [1] The medication was suggested as a potential contraceptive and therapeutic agent. [1]
Megestrol caproate, also known as megestrol 17α-caproate, as well as 17α-hydroxy-6-dehydro-6-methylprogesterone 17α-caproate or as 17α-hydroxy-6-methylpregna-4,6-diene-3,20-dione 17α-caproate, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. [1] [2] It is the C17α caproate (hexanoate) ester of megestrol. [1] [2] Closely related medications include megestrol acetate (MGA; megestrol 17α-acetate), acetomepregenol (megestrol 3β,17α-diacetate), and cymegesolate (megestrol 17α-acetate 3β-cypionate). [3] [4] [5] [6] In addition to MGA, analogues of MGC include chlormadinone caproate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, and methenmadinone caproate.
Note that 3,17-diacetoxy-6-methylpregna-4,6-dien-20-one (1b), a structural analog of compound 1a, is certified in Russia under the trade name acetomepregnol and recommended for therapeutic purposes in gynecological practice and as a contraceptive preparation in combination with estrogens [4].
![]() | |
Clinical data | |
---|---|
Other names | MGC; Megestrol hexanoate; Megestrol 17α-caproate; 17α-Hydroxy-6-dehydro-6-methylprogesterone 17α-caproate; 17α-Hydroxy-6-methylpregna-4,6-diene-3,20-dione 17α-caproate |
Drug class | Progestin; Progestogen; Progestogen ester |
Identifiers | |
| |
PubChem CID | |
ChemSpider | |
Chemical and physical data | |
Formula | C28H40O4 |
Molar mass | 440.624 g·mol−1 |
3D model ( JSmol) | |
| |
|
Megestrol caproate, abbreviated as MGC, is a progestin medication which was never marketed. [1] [2] It was developed in Russia in 2002. [1] In animals, MGC shows 10-fold higher progestogenic activity compared to progesterone when both are administered via subcutaneous injection. [1] In addition, MGC has no androgenic, anabolic, or estrogenic activity. [1] The medication was suggested as a potential contraceptive and therapeutic agent. [1]
Megestrol caproate, also known as megestrol 17α-caproate, as well as 17α-hydroxy-6-dehydro-6-methylprogesterone 17α-caproate or as 17α-hydroxy-6-methylpregna-4,6-diene-3,20-dione 17α-caproate, is a synthetic pregnane steroid and a derivative of progesterone and 17α-hydroxyprogesterone. [1] [2] It is the C17α caproate (hexanoate) ester of megestrol. [1] [2] Closely related medications include megestrol acetate (MGA; megestrol 17α-acetate), acetomepregenol (megestrol 3β,17α-diacetate), and cymegesolate (megestrol 17α-acetate 3β-cypionate). [3] [4] [5] [6] In addition to MGA, analogues of MGC include chlormadinone caproate, gestonorone caproate, hydroxyprogesterone caproate, medroxyprogesterone caproate, and methenmadinone caproate.
Note that 3,17-diacetoxy-6-methylpregna-4,6-dien-20-one (1b), a structural analog of compound 1a, is certified in Russia under the trade name acetomepregnol and recommended for therapeutic purposes in gynecological practice and as a contraceptive preparation in combination with estrogens [4].